A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia

Rasha Kaddoura; Wafer A. Dabdoob; Khalid Ahmed; Mohamed A. Yassin

doi:10.3389/fmed.2023.1163137

A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia

Rasha Kaddoura, Wafer A. Dabdoob, Khalid Ahmed, Mohamed A. Yassin

Research output: Contribution to journal › Review article › peer-review

18 Citations (Scopus)

Abstract

Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML) but their use was associated with a range of serious cardiopulmonary toxicities including vascular adverse events, QT prolongation, heart failure, pleural effusion, and pulmonary arterial hypertension. Dedicated clinical management guidelines for TKI-induced toxicities are not available. This review aims to discuss TKI-associated cardiopulmonary toxicities and proposes a practical guide for their management.

Original language	English (US)
Article number	1163137
Journal	Frontiers in Medicine
Volume	10
DOIs	https://doi.org/10.3389/fmed.2023.1163137
Publication status	Published - 2023
Externally published	Yes

Keywords

QT prolongation
chronic myeloid leukemia
dasatinib
heart failure
pleural effusion
ponatinib
pulmonary arterial hypertension
tyrosine kinase

Access to Document

10.3389/fmed.2023.1163137

Cite this

@article{62a34dc0faee4e038019170ed0637dd6,

title = "A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia",

abstract = "Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML) but their use was associated with a range of serious cardiopulmonary toxicities including vascular adverse events, QT prolongation, heart failure, pleural effusion, and pulmonary arterial hypertension. Dedicated clinical management guidelines for TKI-induced toxicities are not available. This review aims to discuss TKI-associated cardiopulmonary toxicities and proposes a practical guide for their management.",

keywords = "QT prolongation, chronic myeloid leukemia, dasatinib, heart failure, pleural effusion, ponatinib, pulmonary arterial hypertension, tyrosine kinase",

author = "Rasha Kaddoura and Dabdoob, \{Wafer A.\} and Khalid Ahmed and Yassin, \{Mohamed A.\}",

note = "Publisher Copyright: Copyright {\textcopyright} 2023 Kaddoura, Dabdoob, Ahmed and Yassin.",

year = "2023",

doi = "10.3389/fmed.2023.1163137",

language = "English (US)",

volume = "10",

journal = "Frontiers in Medicine",

issn = "2296-858X",

publisher = "Frontiers Media S.A.",

}

TY - JOUR

T1 - A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia

AU - Kaddoura, Rasha

AU - Dabdoob, Wafer A.

AU - Ahmed, Khalid

AU - Yassin, Mohamed A.

PY - 2023

Y1 - 2023

N2 - Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML) but their use was associated with a range of serious cardiopulmonary toxicities including vascular adverse events, QT prolongation, heart failure, pleural effusion, and pulmonary arterial hypertension. Dedicated clinical management guidelines for TKI-induced toxicities are not available. This review aims to discuss TKI-associated cardiopulmonary toxicities and proposes a practical guide for their management.

AB - Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML) but their use was associated with a range of serious cardiopulmonary toxicities including vascular adverse events, QT prolongation, heart failure, pleural effusion, and pulmonary arterial hypertension. Dedicated clinical management guidelines for TKI-induced toxicities are not available. This review aims to discuss TKI-associated cardiopulmonary toxicities and proposes a practical guide for their management.

KW - QT prolongation

KW - chronic myeloid leukemia

KW - dasatinib

KW - heart failure

KW - pleural effusion

KW - ponatinib

KW - pulmonary arterial hypertension

KW - tyrosine kinase

UR - https://www.scopus.com/pages/publications/85159904625

U2 - 10.3389/fmed.2023.1163137

DO - 10.3389/fmed.2023.1163137

M3 - Review article

AN - SCOPUS:85159904625

SN - 2296-858X

VL - 10

JO - Frontiers in Medicine

JF - Frontiers in Medicine

M1 - 1163137

ER -

A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this